Compounded Tirzepatide for Weight Loss

Compounded tirzepatide is a custom-prepared formulation of tirzepatide — the same active pharmaceutical ingredient (API) used in brand-name GLP-1/GIP medications like Zepbound® and Mounjaro®. Compounded versions are prepared on demand by a U.S.-licensed compounding pharmacy after a licensed provider issues a prescription, and they can be tailored to the patient's prescribed dose and schedule rather than sold in fixed pre-filled pens.

Compounded tirzepatide is prepared by U.S.-licensed compounding pharmacies that operate under state pharmacy boards and federal compounding regulations (USP 797 sterile compounding, 503A facility licensing). Compounded medications do not undergo FDA review for safety, efficacy, or manufacturing quality the way brand-name drugs do. Safety depends on the prescribing provider, the pharmacy's compounding standards, the patient's medical history, and adherence to the prescribed protocol. A licensed U.S. clinician reviews every Yucca intake to confirm compounded tirzepatide is appropriate before any prescription is issued.

Compounded tirzepatide from Yucca starts at $258 per month for new patients on the 6-month plan. The shorter 3-month plan is priced slightly higher per month, and the monthly plan is the most flexible. Pricing for refills, longer commitments, and Buy-Now-Pay-Later options (Affirm, Klarna, Afterpay — available on 3- and 6-month plans) is disclosed at checkout once eligibility is confirmed. Free 2-day UPS shipping is included in every plan.

Zepbound® and Mounjaro® are FDA-approved brand-name medications from Eli Lilly that contain tirzepatide as their active ingredient, sold in fixed-dose pre-filled pens. Compounded tirzepatide contains the same active ingredient (tirzepatide) but is prepared on demand by a licensed compounding pharmacy after a provider prescription. Compounded preparations are not FDA-approved and are not directly substitutable with brand-name versions. Compounded tirzepatide is typically less expensive than the brand-name alternatives — though pricing, dose flexibility, and personalization vary by prescriber and pharmacy.

No. Compounded tirzepatide is not FDA-approved. The active ingredient (tirzepatide) is FDA-approved as the substance, but compounded preparations are not reviewed by the FDA for safety, efficacy, or manufacturing quality. Compounded medications are legally prescribed in the United States when a licensed healthcare provider determines them to be clinically appropriate, and they're prepared by U.S.-licensed compounding pharmacies under state and federal pharmacy regulations. Patients should discuss compounded medication framing with their provider before starting treatment.

Compounded tirzepatide for weight loss is typically prescribed for adults with a body mass index (BMI) of 30 or higher, or 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, high cholesterol, etc.). Patients with a BMI above 25 may also qualify depending on medical history. Eligibility is determined case-by-case by a licensed U.S. provider after reviewing the patient's intake. Compounded tirzepatide is not appropriate for patients with a personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, pregnancy, or known hypersensitivity to tirzepatide.

The most common side effects of tirzepatide are gastrointestinal — nausea, diarrhea, vomiting, constipation, indigestion, and abdominal discomfort — and most patients find these are mildest during the first weeks of treatment and ease as the body adjusts. Less common side effects include fatigue, injection-site reactions, decreased appetite (intended), and dizziness. Serious risks include pancreatitis, gallbladder disease, kidney problems, severe hypoglycemia (especially when combined with insulin), and rare allergic reactions. Tirzepatide carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies. See the full Tirzepatide Safety Information page for the complete list of side effects, warnings, and contraindications.

Tirzepatide's appetite-suppressing effects often begin within the first 1–2 weeks of treatment, with most patients noticing reduced hunger and earlier satiety. Measurable weight-loss results typically appear within 4–8 weeks of consistent dosing, with the average patient on tirzepatide losing 15–20% of their baseline body weight over 12 months — though individual results vary based on dose, adherence, diet, exercise, baseline metabolism, and other factors. Providers may gradually titrate the dose upward over the first few months to balance efficacy and tolerability.

At Yucca, the process takes about two minutes upfront. Complete the online intake at quiz.tryyucca.com/wl with your medical history and weight-loss goals. Verify your identity with the last four digits of your SSN or a government-issued ID photo. A U.S.-licensed clinician reviews your submission, typically within 24 hours — no live video appointment required. If you qualify and treatment is appropriate, your prescription is filled by a U.S.-licensed compounding pharmacy and shipped to your door via free UPS 2-Day Air, in insulated packaging that keeps the medication temperature-stable in transit.

Compounded tirzepatide is generally not covered by commercial health insurance plans because compounded medications are not FDA-approved and aren't typically on insurer formularies. Yucca operates as a cash-pay telehealth program — there's no insurance to bill, and pricing is transparent and predictable. The $258/month new-patient pricing on the 6-month plan reflects the all-in cost; there are no insurance copays, prior-authorization delays, or surprise pharmacy bills. Patients who prefer to use HSA/FSA funds can use those cards at checkout where eligible.